Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research.
Bone marrow transplantation
Lost to follow-up
Stem cell transplantation
Survivor
Journal
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
04
09
2019
revised:
24
10
2019
accepted:
03
11
2019
pubmed:
15
11
2019
medline:
24
6
2021
entrez:
15
11
2019
Statut:
ppublish
Résumé
Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects.
Identifiants
pubmed: 31726205
pii: S1083-8791(19)30743-8
doi: 10.1016/j.bbmt.2019.11.003
pmc: PMC7367505
mid: NIHMS1600729
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
553-561Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL150232
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Informations de copyright
Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Références
N Engl J Med. 2017 Mar 9;376(10):947-956
pubmed: 28273021
Lancet Oncol. 2017 Jan;18(1):e30-e38
pubmed: 28049575
J Vasc Surg. 2017 Jun;65(6):1625-1635
pubmed: 28216362
Haematologica. 2019 May;104(5):1084-1092
pubmed: 30514795
Med Pediatr Oncol. 2002 Jul;39(1):2-1; discussion 2
pubmed: 12116072
Biol Blood Marrow Transplant. 2012 May;18(5):708-15
pubmed: 21906576
Biol Blood Marrow Transplant. 2013 Oct;19(10):1498-501
pubmed: 23906634
Blood Adv. 2017 Aug 22;1(19):1617-1627
pubmed: 29296802
J Cancer Surviv. 2016 Oct;10(5):814-31
pubmed: 26920873
Am J Hematol. 2011 Jan;86(1):116-20
pubmed: 21061308
J Cancer Surviv. 2011 Sep;5(3):292-304
pubmed: 21544671
Best Pract Res Clin Haematol. 2008 Jun;21(2):193-204
pubmed: 18503986
Pediatr Blood Cancer. 2018 Nov;65(11):e27364
pubmed: 30024087
Blood. 2010 Oct 28;116(17):3129-39; quiz 3377
pubmed: 20656930
Biol Blood Marrow Transplant. 2010 Aug;16(8):1070-5
pubmed: 20036337
Biol Blood Marrow Transplant. 2012 Mar;18(3):348-71
pubmed: 22178693
PLoS One. 2013 Apr 18;8(4):e61586
pubmed: 23637862
Adolesc Health Med Ther. 2015 Aug 18;6:141-8
pubmed: 26316835
Biol Blood Marrow Transplant. 2015 Feb;21(2):225-32
pubmed: 24999225
Blood Adv. 2019 Feb 12;3(3):397-405
pubmed: 30728138
J Am Coll Cardiol. 2018 Apr 24;71(16):1768-1777
pubmed: 29673467
Am J Clin Oncol. 2018 Oct;41(10):1024-1027
pubmed: 29028642
PLoS One. 2018 Jun 15;13(6):e0198075
pubmed: 29906287
Biol Blood Marrow Transplant. 2016 Apr;22(4):731-743
pubmed: 26746819
Haematologica. 2017 Apr;102(4):614-625
pubmed: 28232372
Biol Blood Marrow Transplant. 2016 Jul;22(7):1319-1323
pubmed: 27013013
J Int AIDS Soc. 2017 Jul 17;20(1):21737
pubmed: 28715158
PLoS One. 2016 Mar 07;11(3):e0150816
pubmed: 26950470
J Psychosoc Oncol. 2011;29(4):394-414
pubmed: 21966725
Biol Blood Marrow Transplant. 2018 Jan;24(1):4-12
pubmed: 28963077
Bone Marrow Transplant. 2016 Feb;51(2):176-81
pubmed: 26642340
Biol Blood Marrow Transplant. 2017 Feb;23(2):184-192
pubmed: 27818318
Front Oncol. 2013 Apr 08;3:75
pubmed: 23580328